Nucleus Hybrid L24 Cochlear Implant System
Cochlear Americas · Decision date Oct 16, 2025
What did the FDA approve?
FDA records P130016/S058 as a supplement to PMA P130016, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Oct 16, 2025.
FDA approval order statement
Cochlear ECochG Measures v3.0 software module within the Cochlear Clinical Extension Platform, to provide compatibility with devices approved under P970051/S225 (CI1000 Series implants, CP1110 Sound Processor, and CP1110S Surgical Processor) and existing acoustic components used with these new devices, in addition to devices already compatible with v2.0. The name of the software module is also changed from v2.0 Cochlear Research Platform ECochG Software module (within Cochlear Research Platform) to v3.0 Cochlear ECochG Measures module (within Cochlear Clinical Extension Platform).
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Oct 16, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P130016/S058
- Regulatory pathway
- PMA supplement
- Applicant
- Cochlear Americas
- Product code
- PGQ
- Decision code
- APPR
- Decision date
- Oct 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cochlear implant with combined electrical stimulation and acoustic amplification.
- Applicant
- Cochlear Americas
- Product code
- PGQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P130016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P130016 · Original PMA
NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM
P130016/S058 received
Application receipt date recorded by FDA.
P130016/S058 · FDA decision
Real-Time Process
P130016/S060 · Related supplement
Cochlear Hybrid Implant System
P130016/S061 · Related supplement
Cochlear Hybrid Implant System
Timeline entries are records held by MedtechLedger for P130016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cochlear Americas | PMA approval | Mar 20, 2014 | FDA | |
Cochlear Hybrid Implant SystemP130016/S060 | Cochlear Americas | PMA supplement | Apr 30, 2026 | FDA |
Cochlear Hybrid Implant SystemP130016/S061 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cochlear Americas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10350 Park Meadows Dr., Lone Tree, CO, 80124
Sources and methodology
- Original FDA record: P130016/S058
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
